Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 207

Sort by

Sort Order Select

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Naveen Pemmaraju, Hagop Kantarjian, Joseph D. Khoury, Nitin Jain, Muzaffar H Qazilbash, Sanam Loghavi, Sherry A. Pierce, Keyur P. Patel, Guillermo Garcia-Manero, Elias Jabbour, Naval Daver, Gautam Borthakur, Marina Konopleva

Blood (2022) 140 (Supplement 1): 1293–1294.

https://doi.org/10.1182/blood-2022-170956

Published: 2022

Journal Articles

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Samuel Urrutia, Koji Sasaki, Rashmi Kanagal-Shamanna, Alex Bataller, Guillermo Montalban-Bravo, Irene Ganan-Gomez, Yue Wei, Hui Yang, Kelly S. Chien, Danielle Hammond, Carlos E. Bueso-Ramos, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 6952–6954.

https://doi.org/10.1182/blood-2022-165488

Published: 2022

Journal Articles

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Robert E. Briski, Kelly S. Chien, Guillermo Montalban-Bravo, Tapan M. Kadia, Elias Jabbour, Naveen Pemmaraju, Koji Sasaki, Danielle Hammond, Nicholas Short, Farhad Ravandi, Yesid Alvarado, Sherry A. Pierce, Guillermo Garcia-Manero, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 4042–4044.

https://doi.org/10.1182/blood-2022-170029

Published: 2022

Journal Articles

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Fadi Haddad, Georgio Medawar, Rashmi Kanagal-Shamanna, Hector Alvarez, Sanam Loghavi, Naval Daver, Sherry A. Pierce, Elias Jabbour, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Hussein A Abbas, Naveen Pemmaraju, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 3196–3198.

https://doi.org/10.1182/blood-2022-169991

Published: 2022

Journal Articles

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Jayastu Senapati, Nicholas Short, Abhishek Maiti, Hussein A Abbas, Naval Daver, Naveen Pemmaraju, Sherry A. Pierce, Kelly S. Chien, Koji Sasaki, Danielle Hammond, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 1427–1429.

https://doi.org/10.1182/blood-2022-169934

Published: 2022

Journal Articles

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

Sai Prasad Desikan, Naval Daver, Sanam Loghavi, Tapan M. Kadia, Nicholas Short, Courtney D. DiNardo, Gautam Borthakur, Sherry A. Pierce, Keyur P. Patel, Hussein A Abbas, Abhishek Maiti, Guillermo Garcia-Manero, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 11788–11790.

https://doi.org/10.1182/blood-2022-166655

Published: 2022

Journal Articles

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia

Fadi Haddad, Koji Sasaki, Ghayas C. Issa, Kunhwa Kim, Jeffrey Skinner, Sara E Dellasala, Yesid Alvarado, Alessandra Ferrajoli, Tapan M. Kadia, Musa Yilmaz, Naveen Pemmaraju, Guillermo Garcia-Manero, Sherry A. Pierce, Elias Jabbour, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 3897–3899.

https://doi.org/10.1182/blood-2022-168604

Published: 2022

Journal Articles

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia

Alex Bataller, Koji Sasaki, Elias Jabbour, Ghayas C. Issa, Fadi Haddad, Jeffrey Skinner, Sara E Dellasala, Guillermo Garcia-Manero, Sherry A. Pierce, Hagop Kantarjian

Blood (2022) 140 (Supplement 1): 3895–3896.

https://doi.org/10.1182/blood-2022-164924

Published: 2022

Journal Articles

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Emmanuel Almanza Huante, Hagop Kantarjian, Kelly S. Chien, Courtney D. DiNardo, Nicholas Short, Abhishek Maiti, Guillermo Montalban-Bravo, Naval Daver, Jitesh D. Kawedia, Kayleigh Bowie, Sherry A. Pierce, Farhad Ravandi, Marina Konopleva, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 3344–3346.

https://doi.org/10.1182/blood-2022-169670

Published: 2022

Journal Articles

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Blood (2022) 140 (Supplement 1): 3324–3326.

https://doi.org/10.1182/blood-2022-158566

Published: 2022

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Blood (2022) 140 (Supplement 1): 4872–4875.

https://doi.org/10.1182/blood-2022-162962

Published: 2022

Journal Articles

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Tareq Abuasab, Fadi Haddad, Shehab Fareed Mohamed, Jeffrey L. Jorgensen, Sa A Wang, Philip A. Thompson, Tapan M. Kadia, Yesid Alvarado, Sherry A. Pierce, Michael J. Keating, David McCue, Hagop Kantarjian, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9385–9386.

https://doi.org/10.1182/blood-2022-165639

Published: 2022

Journal Articles

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Faustine Ong, Nicholas Short, Naval Daver, Tapan M. Kadia, Courtney D. DiNardo, Musa Yilmaz, Yesid Alvarado, Kenneth Vaughan, Sherry A. Pierce, Hagop Kantarjian, Guillermo Garcia-Manero, Farhad Ravandi

Blood (2022) 140 (Supplement 1): 9029–9031.

https://doi.org/10.1182/blood-2022-159110

Published: 2022

Journal Articles

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Blood (2022) 140 (Supplement 1): 6064–6066.

https://doi.org/10.1182/blood-2022-170458

Published: 2022

Journal Articles

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

Tareq Abuasab, Srdan Verstovsek, Gautam Borthakur, Rashmi Kanagal-Shamanna, Keyur Patel, Koichi Takahashi, Lucia Masarova, Prithviraj Bose, John Villarreal, Sherry A. Pierce, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Nicholas Short, Courtney D. DiNardo, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Musa Yilmaz

Blood (2022) 140 (Supplement 1): 8954–8956.

https://doi.org/10.1182/blood-2022-165455

Published: 2022

Journal Articles

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Blood (2022) 140 (Supplement 1): 6306–6308.

https://doi.org/10.1182/blood-2022-164494

Published: 2022

Journal Articles

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 2267–2269.

https://doi.org/10.1182/blood-2022-162892

Published: 2022

Journal Articles

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies

Sangeetha Venugopal, Sanam Loghavi, Mark Routbort, Fatima Zahra Jelloul, Rashmi Kanagal-Shamanna, Sherry A. Pierce, Ghayas C. Issa, Hussein A Abbas, Koji Sasaki, Koichi Takahashi, Naval Daver, Farhad Ravandi, Hagop Kantarjian, Courtney D. DiNardo

Blood (2022) 140 (Supplement 1): 6328–6330.

https://doi.org/10.1182/blood-2022-169778

Published: 2022

Journal Articles

Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy

Jayastu Senapati, Hagop Kantarjian, Farhad Ravandi, Courtney D. DiNardo, Koichi Takahashi, Danielle Hammond, Koji Sasaki, Kelly S. Chien, Rashmi Kanagal-Shamanna, Uday R Popat, Sherry A. Pierce, Elias Jabbour, Richard E Champlin, Guillermo Garcia-Manero, Tapan M. Kadia

Blood (2022) 140 (Supplement 1): 8652–8654.

https://doi.org/10.1182/blood-2022-170447

Published: 2022

Journal Articles

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Blood (2022) 140 (Supplement 1): 141–144.

https://doi.org/10.1182/blood-2022-170188

Published: 2022

NARROW

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Long-Term Outcomes and Novel Observations from a Large BPDCN Cohort

Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)

Del5q with One Additional Cytogenetic Abnormality Other Than Del20q Identifies a Higher Risk Population of MDS Patients

Evaluation of Emergent FLT3 Mutations (FLT3m) at Relapse in Patients (Pts) with Wild-Type FLT3 Acute Myeloid Leukemia (AML)

Splicing Gene Mutations Do Not Affect Outcomes in Newly Diagnosed Patients with Acute Myeloid Leukemia

Non-Canonical FLT3 Mutations (FLT3m) in Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) - Outcomes and Prognosis after FLT3 Inhibitor (FLT3i) and Venetoclax Based Regimens

More Than Ten Years Follow-up of Frontline Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myeloid Leukemia

Prognostic Model of Transformation to Blast Phase in Patients with Chronic Myeloid Leukemia

Uproleselan Added to Cladribine Plus Low Dose Cytarabine (LDAC) in Patients with Treated Secondary Acute Myeloid Leukemia (TS-AML)

Phase 2 Study of ASTX727 (cedazuridine/decitabine) Plus Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) or Previously Untreated, Elderly Patients with AML Unfit for Chemotherapy

Allogeneic Hematopoietic Stem Cell Transplantation in Older Patients with Acute Myeloid Leukemia: Analysis of Outcomes and Contemporary Trends Spanning 10 Years

Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

The Frequency and Clinical Implications of ASXL2 Mutations in Myeloid Neoplasms

The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency

Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia

Clinical and Molecular Characterization of Newly Diagnosed IDH/TP53 Co-Mutated AML and Impact of Genomically Sensitive Treatment Strategies

Outcomes of Older Patients with Aplastic Anemia Treated with Frontline Anti-Thymocyte Globulin (ATG)-Based Immunosuppressive Therapy

Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only